|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Investments: | ||||||||||||||||
| Fixed maturity securities, available-for-sale, at fair value (net of allowance for credit losses of $5,910 and $7,000, respectively) (amortized cost of $2,265,283 and $1,848,755, respectively) | ||||||||||||||||
| Fixed maturity securities, held-to-maturity, at amortized cost (net of allowance for credit losses of $4,228 and $468, respectively) | ||||||||||||||||
| Equity securities, at fair value | ||||||||||||||||
| Mortgage loans, at fair value | ||||||||||||||||
| Equity method investments | ||||||||||||||||
| Other long-term investments | ||||||||||||||||
| Short-term investments, at fair value | ||||||||||||||||
| Total investments | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Restricted cash | ||||||||||||||||
| Funds at Lloyd’s | ||||||||||||||||
| Options, at fair value | ||||||||||||||||
| Premiums and commissions receivable, net | ||||||||||||||||
| Reinsurance recoverables, net | ||||||||||||||||
| Ceded unearned premium | ||||||||||||||||
| Deferred policy acquisition costs and VOBA | ||||||||||||||||
| Deferred tax assets | ||||||||||||||||
| Goodwill and intangible assets, net | ||||||||||||||||
| Other assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||
| Liabilities: | ||||||||||||||||
| Reserves for losses and loss adjustment expenses | ||||||||||||||||
| Unearned premiums | ||||||||||||||||
| Deferred ceding commission | ||||||||||||||||
| Reinsurance and premium payables | ||||||||||||||||
| Funds held for others | ||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||
| Notes payable | ||||||||||||||||
| Subordinated debt, net of debt issuance costs | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Stockholders’ equity | ||||||||||||||||
| Series A preferred stock, $0.01 par value; 10,000,000 and 2,000,000 shares authorized, 0 and 1,969,660 shares issued and outstanding, respectively | ||||||||||||||||
| Common stock, $0.01 par value, 500,000,000 shares authorized, 44,846,532 shares issued and 44,413,449 shares outstanding at September 30, 2026; 40,511,222 shares issued and outstanding at December 31, 2025 | ||||||||||||||||
| Treasury stock, at cost, 433,083 and 0 shares, respectively | ||||||||||||||||
| Additional paid-in capital | ||||||||||||||||
| Stock notes receivable | ||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||
| Retained earnings | ||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...